Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data

Rheumatology and Therapy
doi 10.1007/s40744-019-00183-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Incidence of Gastrointestinal Perforations in Patients With Rheumatoid Arthritis Treated With Tocilizumab From Clinical Trial, Postmarketing, and Real-World Data Sources

Rheumatology and Therapy
2016English

NK Cell Count as Predictor of Clinical Response in Patients With Rheumatoid Arthritis Treated With Rituximab

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

Journal of Rheumatology
RheumatologyAllergyImmunology
2010English

Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients With Rheumatoid Arthritis in Japan

Journal of Rheumatology
RheumatologyAllergyImmunology
2013English

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry

Arthritis Care and Research
Rheumatology
2019English

OP0105 Long-Term Safety of Tocilizumab From Large Clinical Trial and Postmarketing Populations

2017English

Serological Markers Associated With Disease Activity in Patients With Rheumatoid Arthritis Treated With Rituximab

Journal of International Medical Research
BiochemistryMedicineCell Biology
2016English

Safety of Rituximab in Rheumatoid Arthritis

Reumatismo
Rheumatology
2011English

Long-Term Safety and Effectiveness of Adalimumab for the Treatment of Japanese Patients With Rheumatoid Arthritis: 3-Year Results From a Postmarketing Surveillance of 552 Patients

Modern Rheumatology
MedicineRheumatology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy